Christine Mikail Cvijic Sells 4,200 Shares of Neurogene (NASDAQ:NGNE) Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 4,200 shares of the firm’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $36.13, for a total transaction of $151,746.00. Following the completion of the transaction, the chief financial officer directly owned 84,040 shares of the company’s stock, valued at $3,036,365.20. This represents a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Monday, July 6th, Christine Mikail Cvijic sold 600 shares of Neurogene stock. The stock was sold at an average price of $36.02, for a total value of $21,612.00.
• On Thursday, July 2nd, Christine Mikail Cvijic sold 4,061 shares of Neurogene stock. The shares were sold at an average price of $34.82, for a total value of $141,404.02.
• On Wednesday, July 1st, Christine Mikail Cvijic sold 739 shares of Neurogene stock. The stock was sold at an average price of $34.06, for a total value of $25,170.34.
• On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The shares were sold at an average price of $31.25, for a total value of $300,000.00.

Neurogene Price Performance

NGNE stock traded up $4.24 during midday trading on Tuesday, reaching $36.80. 708,181 shares of the company were exchanged, compared to its average volume of 246,656. Neurogene Inc. has a one year low of $15.93 and a one year high of $37.27. The firm has a market capitalization of $581.44 million, a price-to-earnings ratio of -8.09 and a beta of 1.68. The business has a 50-day moving average price of $29.70 and a two-hundred day moving average price of $23.57.

Neurogene (NASDAQ:NGNE) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.09). As a group, analysts anticipate that Neurogene Inc. will post -5.63 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on NGNE. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a research report on Tuesday, April 21st. Rodman & Renshaw began coverage on Neurogene in a research note on Wednesday, June 3rd. They set a “buy” rating and a $70.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Neurogene in a report on Tuesday, June 9th. UBS Group set a $70.00 target price on Neurogene in a report on Wednesday, June 3rd. Finally, Guggenheim initiated coverage on Neurogene in a research report on Tuesday, April 28th. They issued a “buy” rating and a $69.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Neurogene has an average rating of “Buy” and a consensus target price of $84.83.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Balyasny Asset Management L.P. acquired a new stake in shares of Neurogene in the 3rd quarter valued at approximately $12,114,000. ArrowMark Colorado Holdings LLC grew its holdings in shares of Neurogene by 1.8% during the third quarter. ArrowMark Colorado Holdings LLC now owns 595,839 shares of the company’s stock worth $10,326,000 after purchasing an additional 10,442 shares during the last quarter. Jennison Associates LLC increased its position in Neurogene by 35.3% in the 4th quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock valued at $10,982,000 after acquiring an additional 138,999 shares during the period. State Street Corp increased its holdings in Neurogene by 47.8% in the fourth quarter. State Street Corp now owns 307,797 shares of the company’s stock valued at $6,341,000 after purchasing an additional 99,487 shares during the period. Finally, Geode Capital Management LLC raised its position in Neurogene by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 249,695 shares of the company’s stock worth $5,145,000 after purchasing an additional 3,262 shares during the last quarter. Institutional investors and hedge funds own 52.37% of the company’s stock.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.